article · Pharmaceutics
Acne vulgaris is a widespread skin condition driven by bacterial overgrowth from imbalanced skin flora. To improve therapy, researchers developed clindamycin molecularly imprinted polymeric nanoparticles incorporated into polyurethane nanofibrous scaffolds. The nanoparticles were synthesised using precipitation polymerisation and integrated into polyurethane fibres via electrospinning. The formulation exhibited potent antibacterial action against Staphylococcus aureus, delivering bactericidal activity within 180 minutes in vitro. In animal studies, the scaffold substantially lowered bacterial counts from one hundred million to 390 colony-forming units per millilitre. Histopathological and pharmacodynamic assessments in infected animal skin showed marked reductions in inflammation, epidermal hypertrophy, and tissue congestion. Furthermore, treatment reduced levels of key pro-inflammatory cytokines, including NLRP3, TNF-alpha, IL-1beta, and IL-6, supporting tissue healing in acne-related infectious wounds.
Acne affects millions of people globally and requires treatments that effectively clear bacterial infection while managing tissue inflammation. By combining targeted nanoparticle drug delivery with nanofibre scaffolds, this approach tackles both microbial overgrowth and inflammatory tissue damage. Demonstrating rapid antibacterial action and reduced cytokine levels in animal models presents a promising strategy for enhancing topical acne therapies.
This technology is relevant to pharmaceutical and wound-care product developers targeting dermatological conditions such as acne vulgaris. The formulation could enable topical nanofibrous dressings or patches that deliver controlled antibiotic therapy directly to infected skin lesions. As the research currently encompasses in vitro and preclinical animal testing, it remains at an applied laboratory stage and requires formal clinical trials before real-world medical deployment.
AI-generated from the published abstract. Always read the original work before citing.
Acne vulgaris, a prevalent skin condition, arises from an imbalance in skin flora, fostering bacterial overgrowth. Addressing this issue, clindamycin molecularly imprinted polymeric nanoparticles (Clin-MIP) loaded onto polyurethane nanofiber scaffolds were developed for acne treatment. Clin-MIP was synthesized via precipitation polymerization using methacrylic acid (MAA), ethylene glycol dimethacrylate (EGDMA), and azoisobutyronitrile (AIBN) as functional monomers, crosslinkers, and free-radical initiators, respectively. MIP characterization utilized Fourier-transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM) before being incorporated into polyurethane nanofibers through electrospinning. Further analysis involved FTIR, scanning electron microscopy (SEM), in vitro release studies, and an ex vivo study. Clin-MIP showed strong antibacterial activity against S. aureus, with inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of 0.39 and 6.25 μg/mL, respectively. It significantly dropped the bacterial count from 1 × 108 to 39 × 101 CFU/mL in vivo and has bactericidal activity within 180 min of incubation in vitro. The pharmacodynamic and histopathology studies revealed a significant decrease in infected animal skin inflammation, epidermal hypertrophy, and congestion upon treatment with Clin-MIP polyurethane nanofiber and reduced pro-inflammatory cytokines (NLRP3, TNF-α, IL-1β, and IL-6) conducive to acne healing. Consequently, the recently created Clin-MIP polyurethane nanofibrous scaffold. This innovative approach offers insight into creating materials with several uses for treating infectious wounds caused by acne.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/pharmaceutics16070947
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
